Lamark Biotech

Private

LAMARK BIOTECH PRIVATE LIMITED

Private

LAMARK BIOTECH PRIVATE LIMITED

2018

Founded in 2018, Lamark Biotech operates in Health Tech offering innovative molecular medicines to support sustainable and affordable healthcare systems globally. The company focuses on developing the...

Funding stage:

Pre-Series A

Last funding:

30/06/2025

Total funding:

$760.22K+

Revenue:

₹1.1 Cr+ (FY25)

Prev. FY

Investors

Employee count:

Last 90d

Web traffic:

1.08K

Last 30d

Lamark Biotech: Financial Breakdown

Decoding financial health metrics of Lamark Biotech

Total Revenue
₹1.1 Cr
2354%
Prev. FY
Total Expenses
₹1.7 Cr
149%
Prev. FY
Profit After Tax
₹-56.7 Lakh
11%
Prev. FY
Total Assets
₹5.2 Cr
101%
Prev. FY

Note: Above mentioned stats are for FY24-25

FAQs on Financials of Lamark Biotech

No. In FY25, Lamark Biotech reported a net loss of ₹98.4 Lakh, so it was not profitable.

Lamark Biotech's estimated EBITDA for FY25 was ₹-88.9 Lakh, derived from its profit before tax, finance costs, and depreciation & amortisation.

In FY25, Lamark Biotech posted revenue of ₹3.3 Cr and a net loss of ₹98.4 Lakh. Explore the full financials of Lamark Biotech here...

Disclaimer

Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.

Quick Links

Lamark Biotech - Financials, Revenue, P&L Statement, Balance Sheet, Cash Flow & More

Lamark Biotech: Financial Breakdown

FAQs on Financials of Lamark Biotech

Is Lamark Biotech profitable?

What is Lamark Biotech's EBITDA?

How is Lamark Biotech's business performing?

Disclaimer